BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20523089)

  • 21. A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
    Carter J; Durfee J
    Gynecol Oncol; 2007 Dec; 107(3):586-9. PubMed ID: 17949798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical procedures and morbidities of diaphragmatic surgery in patients undergoing initial or interval debulking surgery for advanced-stage ovarian cancer.
    Gouy S; Chereau E; Custodio AS; Uzan C; Pautier P; Haie-Meder C; Duvillard P; Morice P
    J Am Coll Surg; 2010 Apr; 210(4):509-14. PubMed ID: 20347745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical treatment of epithelial ovarian cancer.
    González-Martín AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and management of epithelial ovarian cancer.
    Bhoola S; Hoskins WJ
    Obstet Gynecol; 2006 Jun; 107(6):1399-410. PubMed ID: 16738170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indicators of survival duration in ovarian cancer and implications for aggressiveness of care.
    von Gruenigen V; Daly B; Gibbons H; Hutchins J; Green A
    Cancer; 2008 May; 112(10):2221-7. PubMed ID: 18348300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy for advanced ovarian cancer.
    Schwartz PE; Chambers JT; Makuch R
    Gynecol Oncol; 1994 Apr; 53(1):33-7. PubMed ID: 8175019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Williams K; Senterman M; Hopkins L; Faught W; Fung-Kee-Fung M
    Gynecol Oncol; 2007 Jul; 106(1):160-3. PubMed ID: 17490737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognostic factors of ovarian cancer].
    Ochiai K
    Gan To Kagaku Ryoho; 2006 Dec; 33(13):2014-9. PubMed ID: 17197745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian cancer chemotherapy.
    Christian J; Thomas H
    Cancer Treat Rev; 2001 Apr; 27(2):99-109. PubMed ID: 11319848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection.
    Tanaka K; Shimada H; Togo S; Takahashi T; Endo I; Sekido H; Yoshida T
    Hepatogastroenterology; 1999; 46(26):1083-8. PubMed ID: 10370671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
    Mehta RS
    J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
    [No Abstract]   [Full Text] [Related]  

  • 33. Update on the management of ovarian cancer.
    Ozols RF
    Cancer J; 2002; 8 Suppl 1():S22-30. PubMed ID: 12075699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Value of tumor-reductive secondary operation (interventional laparotomy) in ovarian cancer].
    Meier W; Römisch M; Hepp H
    Geburtshilfe Frauenheilkd; 1993 Dec; 53(12):860-5. PubMed ID: 8119569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic strategies in colorectal cancer].
    Flieger D; Keller R; Fischbach W
    Dtsch Med Wochenschr; 2003 Sep; 128(37):1902-7. PubMed ID: 12970825
    [No Abstract]   [Full Text] [Related]  

  • 36. Role of chemotherapy in the management of epithelial ovarian cancer.
    Reed NS; Sadozye AH
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):139-47. PubMed ID: 15757446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
    Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacotherapy in ovarian carcinoma].
    Pfisterer J; Du Bois A
    MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer.
    Kitchener HC
    Cancer Treat Rev; 2005 Jun; 31(4):323-7. PubMed ID: 15905036
    [No Abstract]   [Full Text] [Related]  

  • 40. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist].
    Sugiyama T; Yoshizaki A; Hatayama S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1011-6. PubMed ID: 17637537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.